The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

• Main Authors: Marco, H, Smith, R.M, Jones, R.B, Guerry, M.-J, Catapano, F, Burns, S, Chaudhry, A.N, Smith, K.G, Jayne, D.R
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: alemtuzumab; antineoplastic agent; azathioprine; cyclophosphamide; glucocorticoid; hydroxychloroquine; immunoglobulin; immunoglobulin A; immunoglobulin G; immunoglobulin M; methotrexate; methylprednisolone; mycophenolic acid 2 morpholinoethyl ester; prednisolone; rituximab; immunologic factor; monoclonal antibody; adolescent; adult; aged; anaphylactoid purpura; article; autoimmune disease; Behcet disease; Churg Strauss syndrome; controlled study; disease activity; disease duration; drug effect; female; follow up; human; immunoglobulin blood level; immunoglobulin deficiency; immunotherapy; infection rate; maintenance therapy; major clinical study; male; microscopic polyangiitis; multisystem autoimmune disease; randomized controlled trial (topic); retrospective study; systemic lupus erythematosus; systemic vasculitis; treatment duration; treatment response; Wegener granulomatosis; agammaglobulinemia; Autoimmune Diseases; blood; chemically induced; middle aged; treatment outcome; very elderly; young adult; Adolescent; Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Female; Follow-Up Studies; Humans; Immunoglobulins; Immunologic Factors; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181500
• Institution: National University of Singapore

10.1186/1471-2474-15-178